扶正补虚方对原发性肝癌患者T细胞亚群及血管生成相关因子影响

Effect of Fuzhengbuxu decotion on T cell subsets and angiogenesis related factors of patients with primary hepatic carcinoma

目的探讨扶正补虚方治疗原发性肝癌治疗效果及对患者免疫功能和血管生长因子的影响。方法将86例原发性肝癌患者采用随机数字表法分为观察组与对照组,对照组给予常规化疗方案,观察组在对照组基础上联合扶正补虚方治疗,记录两组疗效。结果观察组治疗总有效率为32.6%(14/43),对照组治疗总有效率为14.0%(6/43),差异有统计学意义(P<0.05)。观察组治疗后CD3+T(65.98±7.83),CD4+T(41.02±5.27),CD8+T(21.34±2.05),CD4+T/CD8+T(1.59±0.84);对照组治疗后CD3+T(52.93±5.24),CD4+T(31.89±4.11),CD8+T(34.85±4.59),CD4+T/CD8+T(1.03±0.45),差异有统计学意义(P<0.05)。观察组治疗后血管内皮生长因子(VEGF)(21.05±5.78)ng/L,基质蛋白酶9(MMP-9)(6.11±2.41)ng/L;对照组治疗后VEGF(29.02±9.97)ng/L,MMP-9(9.63±4.01)ng/L,差异有统计学意义(P<0.05)。结论采用扶正补虚方可以提高原发性肝癌临床疗效,通过改善肝癌患者细胞免疫功能,抑制患者血清VEGF和MMP-9浓度,值得在临床上推广应用。

Objective To explore the effect of Fuzhengbuxu decotionon on the immune function and vascular growth factors in patients with primary liver carcinoma.Methods According to random number table method,86 patients with primary werer carcinoma were divided into observation group and control group.Control group received conventional chemotherapy regimens, observation group got conventional chemotherapy regimens plus the Fuzhengbuxu decotion.Curative effects were observed between the two groups.Results Total effectiveness of treatment group was 32.6%（14/43）,that of control group was 14.0%（6/43）（P 〈0.05）.After treatment,CD3 ＋ , CD4 ＋ ,CD8 ＋ ,CD4 ＋/CD8 ＋ of oberservation group were respectively （65.98±7.83）,（41.02±5.27）,（21.34±2.05）, （1.59±0.84）;those of the control group were （52.93±5.24）,（31.89±4.1 1）,（34.85±4.59）,（1.03 ±0.45）（P 〈0.05）.After treatment,serum vascular endothelial growth factor（VEGF）and matrix metalloproteinases-9（MMP-9） of observation group were （21.05 ± 5.78 ）ng/L and （6.1 1 ± 2.41 ）ng/L respectively;VEGF and MMP-9 of the control group were （29.02 ± 9.97 ）ng/L and （9.63 ± 4.01 ）ng/L（P 〈 0.05 ）.Conclusion Fuzhengbuxu decotion could improve the clinical efficacy of primary liver carcinoma,by improving cellular immune function and suppressing concentration of serumVEGF and MMP-9,the medicine deserves the clinical expansion application.